Bladder and Renal
The following list provides a brief description of bladder and renal cancer trials that are recruiting participants in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
EVERSUN Study
|
Registered Title |
A phase 2 trial of Everolimus alternating with Sunitinib as first line therapy for advanced renal cell carcinoma. |
|
Purpose |
This study looks at the effectiveness of the chemotherapy drugs Everolimus and Sunitinib, used in sequence, in treating people with advanced renal cell carcinoma.
Who is it for? You can join this study if you have renal cell (kidney) cancer that has spread to distant sites and is at an advanced stage.
Trial details: Participants will all receive the same treatment. This involves six-weekly cycles comprising four weeks of sunitinib 50 mg once daily followed by two weeks rest The second cycle comprises five weeks of everolimus 10 mg once daily followed by one weeks rest. The study aims to see the effectiveness of treatment by looking at survival and disease progression in patients after six months. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
Fremantle Hospital |
|
Links |
Acknowledgements: Australian New Zealand Clinical Trials Registry
SORCE Study
|
Registered Title |
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse. |
|
Purpose |
This randomized phase III trial is studying sorafenib to see how well it works compared with a placebo in treating patients at risk of relapse after undergoing surgery to remove kidney cancer.
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sorafenib is more effective than a placebo in treating kidney cancer. |
|
Lay Summary |
This study is for patients who have had a kidney cancer that has been surgically removed and there is no visible evidence of cancer left in their body, but who are considered to be at risk of the cancer returning. These types of patients would normally not have any further treatment. The purpose of the trial is to see if giving the patients a drug that is used in advanced kidney cancer (the kidney cancer has spread) can stop the cancer from returning. Patients will be randomised to receive one of three possible treatments: three years of placebo or one year of the drug followed by two years of placebo or three years of the drug. |
|
WA Trial Sites |
Fremantle Hospital
RPH Medical Oncology
SCGH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
